Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: Results from a historic cohort

M. Barba, F. Sperati, S. Stranges, C. Carlomagno, G. Nasti, V. Iaffaioli, G. Caolo, M. Mottolese, G. Botti, I. Terrenato, P. Vici, D. Serpico, A. Giordano, G. D'Aiuto, A. Crispo, M. Montella, G. Capurso, G. Delle fave, B. Fuhrman, C. BottiS. De Placido

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: We investigated pretreatment fasting glucose as a predictor of patients' important outcomes in breast and colorectal cancers undergoing targeted therapies. Patients and methods: In a historic cohort of 202 breast and 218 colorectal cancers treated with targeted agents from 1998 to 2009, we used the Kaplan-Meier method and the log-rank test to estimate survival through tertiles of fasting glucose and the Cox proportional hazards model for multivariate analysis stratified by primary site of cancer and including gender, age and body mass index. Results: The median follow-up was 20 months (1-128). At 60 months, 65% of patients in the lowest tertile of fasting glucose did not experiment disease progression compared with 34% in the highest tertile (P = 0.001). Seventy-six percent of females in the lowest tertile showed no progression compared with 49% in the top tertiles (P = 0.015). In multivariate analysis, fasting glucose was a significant predictor of time to disease progression only in breast cancer patients in the first tertile compared with the third (P = 0.017). Conclusions: We found evidence of a predictive role of pretreatment fasting glucose in the development of resistance in breast cancer patients treated with targeted agents. Prospective studies are warranted to confirm our findings.

Original languageEnglish
Article numbermdr540
Pages (from-to)1838-1845
Number of pages8
JournalAnnals of Oncology
Volume23
Issue number7
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Colorectal Neoplasms
Fasting
Breast Neoplasms
Glucose
Disease Progression
Multivariate Analysis
Proportional Hazards Models
Breast
Body Mass Index
Prospective Studies
Survival
Neoplasms
Therapeutics

Keywords

  • Breast cancer
  • Colorectal cancer
  • Fasting glucose
  • Targeted agents

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents : Results from a historic cohort. / Barba, M.; Sperati, F.; Stranges, S.; Carlomagno, C.; Nasti, G.; Iaffaioli, V.; Caolo, G.; Mottolese, M.; Botti, G.; Terrenato, I.; Vici, P.; Serpico, D.; Giordano, A.; D'Aiuto, G.; Crispo, A.; Montella, M.; Capurso, G.; Delle fave, G.; Fuhrman, B.; Botti, C.; De Placido, S.

In: Annals of Oncology, Vol. 23, No. 7, mdr540, 07.2012, p. 1838-1845.

Research output: Contribution to journalArticle

Barba, M, Sperati, F, Stranges, S, Carlomagno, C, Nasti, G, Iaffaioli, V, Caolo, G, Mottolese, M, Botti, G, Terrenato, I, Vici, P, Serpico, D, Giordano, A, D'Aiuto, G, Crispo, A, Montella, M, Capurso, G, Delle fave, G, Fuhrman, B, Botti, C & De Placido, S 2012, 'Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: Results from a historic cohort', Annals of Oncology, vol. 23, no. 7, mdr540, pp. 1838-1845. https://doi.org/10.1093/annonc/mdr540
Barba, M. ; Sperati, F. ; Stranges, S. ; Carlomagno, C. ; Nasti, G. ; Iaffaioli, V. ; Caolo, G. ; Mottolese, M. ; Botti, G. ; Terrenato, I. ; Vici, P. ; Serpico, D. ; Giordano, A. ; D'Aiuto, G. ; Crispo, A. ; Montella, M. ; Capurso, G. ; Delle fave, G. ; Fuhrman, B. ; Botti, C. ; De Placido, S. / Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents : Results from a historic cohort. In: Annals of Oncology. 2012 ; Vol. 23, No. 7. pp. 1838-1845.
@article{ed33690b3cef4763a8bebca2f8b76721,
title = "Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: Results from a historic cohort",
abstract = "Background: We investigated pretreatment fasting glucose as a predictor of patients' important outcomes in breast and colorectal cancers undergoing targeted therapies. Patients and methods: In a historic cohort of 202 breast and 218 colorectal cancers treated with targeted agents from 1998 to 2009, we used the Kaplan-Meier method and the log-rank test to estimate survival through tertiles of fasting glucose and the Cox proportional hazards model for multivariate analysis stratified by primary site of cancer and including gender, age and body mass index. Results: The median follow-up was 20 months (1-128). At 60 months, 65{\%} of patients in the lowest tertile of fasting glucose did not experiment disease progression compared with 34{\%} in the highest tertile (P = 0.001). Seventy-six percent of females in the lowest tertile showed no progression compared with 49{\%} in the top tertiles (P = 0.015). In multivariate analysis, fasting glucose was a significant predictor of time to disease progression only in breast cancer patients in the first tertile compared with the third (P = 0.017). Conclusions: We found evidence of a predictive role of pretreatment fasting glucose in the development of resistance in breast cancer patients treated with targeted agents. Prospective studies are warranted to confirm our findings.",
keywords = "Breast cancer, Colorectal cancer, Fasting glucose, Targeted agents",
author = "M. Barba and F. Sperati and S. Stranges and C. Carlomagno and G. Nasti and V. Iaffaioli and G. Caolo and M. Mottolese and G. Botti and I. Terrenato and P. Vici and D. Serpico and A. Giordano and G. D'Aiuto and A. Crispo and M. Montella and G. Capurso and {Delle fave}, G. and B. Fuhrman and C. Botti and {De Placido}, S.",
year = "2012",
month = "7",
doi = "10.1093/annonc/mdr540",
language = "English",
volume = "23",
pages = "1838--1845",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "7",

}

TY - JOUR

T1 - Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents

T2 - Results from a historic cohort

AU - Barba, M.

AU - Sperati, F.

AU - Stranges, S.

AU - Carlomagno, C.

AU - Nasti, G.

AU - Iaffaioli, V.

AU - Caolo, G.

AU - Mottolese, M.

AU - Botti, G.

AU - Terrenato, I.

AU - Vici, P.

AU - Serpico, D.

AU - Giordano, A.

AU - D'Aiuto, G.

AU - Crispo, A.

AU - Montella, M.

AU - Capurso, G.

AU - Delle fave, G.

AU - Fuhrman, B.

AU - Botti, C.

AU - De Placido, S.

PY - 2012/7

Y1 - 2012/7

N2 - Background: We investigated pretreatment fasting glucose as a predictor of patients' important outcomes in breast and colorectal cancers undergoing targeted therapies. Patients and methods: In a historic cohort of 202 breast and 218 colorectal cancers treated with targeted agents from 1998 to 2009, we used the Kaplan-Meier method and the log-rank test to estimate survival through tertiles of fasting glucose and the Cox proportional hazards model for multivariate analysis stratified by primary site of cancer and including gender, age and body mass index. Results: The median follow-up was 20 months (1-128). At 60 months, 65% of patients in the lowest tertile of fasting glucose did not experiment disease progression compared with 34% in the highest tertile (P = 0.001). Seventy-six percent of females in the lowest tertile showed no progression compared with 49% in the top tertiles (P = 0.015). In multivariate analysis, fasting glucose was a significant predictor of time to disease progression only in breast cancer patients in the first tertile compared with the third (P = 0.017). Conclusions: We found evidence of a predictive role of pretreatment fasting glucose in the development of resistance in breast cancer patients treated with targeted agents. Prospective studies are warranted to confirm our findings.

AB - Background: We investigated pretreatment fasting glucose as a predictor of patients' important outcomes in breast and colorectal cancers undergoing targeted therapies. Patients and methods: In a historic cohort of 202 breast and 218 colorectal cancers treated with targeted agents from 1998 to 2009, we used the Kaplan-Meier method and the log-rank test to estimate survival through tertiles of fasting glucose and the Cox proportional hazards model for multivariate analysis stratified by primary site of cancer and including gender, age and body mass index. Results: The median follow-up was 20 months (1-128). At 60 months, 65% of patients in the lowest tertile of fasting glucose did not experiment disease progression compared with 34% in the highest tertile (P = 0.001). Seventy-six percent of females in the lowest tertile showed no progression compared with 49% in the top tertiles (P = 0.015). In multivariate analysis, fasting glucose was a significant predictor of time to disease progression only in breast cancer patients in the first tertile compared with the third (P = 0.017). Conclusions: We found evidence of a predictive role of pretreatment fasting glucose in the development of resistance in breast cancer patients treated with targeted agents. Prospective studies are warranted to confirm our findings.

KW - Breast cancer

KW - Colorectal cancer

KW - Fasting glucose

KW - Targeted agents

UR - http://www.scopus.com/inward/record.url?scp=84864302743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864302743&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdr540

DO - 10.1093/annonc/mdr540

M3 - Article

C2 - 22100694

AN - SCOPUS:84864302743

VL - 23

SP - 1838

EP - 1845

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

M1 - mdr540

ER -